β2-glycoprotein I–dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome

Laat, H. Bas de; Derksen, R. H. W. M.; Urbanus, Rolf T.; Roest, Mark; Groot, Philip G. de

doi:10.1182/blood-2004-03-1107

Cited by 208 publications

(214 citation statements)

References 18 publications

Supporting

Mentioning

201

Contrasting

Unclassified

Order By: Relevance

“…The combinations SCT/dRVVT and dRVVT/APTT were both associated with IgG antibodies to b 2 -GPI. The significant association of SCT alone or combined with dRVVT with the most clinically important aPLELISAs, such as IgG anti-b 2 -GPI and IgG aCL (16)(17)(18), underlines its important clinical value. These results confirm that this new commercial SCT assay is a sensitive and specific test for diagnosing LA in patients with APS-related thrombosis.…”

Section: Discussionmentioning

confidence: 99%

“…In a recent work de Laat et al (18) reported that antib 2 -GPI with LA activity are antibodies that are responsible for thrombosis in patients affected with APS. In our study SCT and dRVVT were significantly associated with IgG anti-b 2 -GPI antibodies, while APTT was associated only with IgG and IgM aCL.…”

Section: Discussionmentioning

confidence: 99%

“…However, the activated partial thromboplastin time (APTT), in which a lupus-sensitive APTT reagent is used (10)(11)(12)18), and the dilute Russell's viper venom time (dRVVT) are currently the most frequently utilized assays (11).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Use of a new silica clotting time for diagnosing lupus anticoagulant in patients who meet the clinical criteria for antiphospholipid syndrome

Grypiotis

Ruffatti

Pengo

et al. 2006

Clinical Laboratory Analysis

View full text Add to dashboard Cite

The silica clotting time (SCT) is a phospholipid-dependent coagulation assay used for the laboratory diagnosis of lupus anticoagulant (LA) antibodies. The sensitivity and specificity of a new commercial SCT for identifying LA in patients who meet the clinical criteria for antiphospholipid syndrome (APS), and its association with thrombotic events were evaluated here. Forty-five patients who met the clinical criteria for APS according to the Sapporo International Consensus Statement were examined. Sixty-nine patients who did not meet the clinical criteria for APS, and 20 blood donors were used as controls. Plasma samples from the patients and controls were tested for LA using a new commercial SCT with low and high synthetic phospholipid concentrations. The results were compared with those obtained by diluted Russell's viper venom time (dRVVT) and activated partial thromboplastin time (APTT). SCT's sensitivity for identifying LA in patients who met the clinical criteria of APS was higher compared to APTT and dRVVT (53.3% vs. 31.1% and 31.1%), and the specificities of these assays were 96.6%, 100%, and 98.9%, respectively. When dRVVT was combined with SCT, and dRVVT was combined with APTT their sensitivities were 57.7% and 48.8%, and their specificities were 96.6% and 98.9%, respectively. A stepwise logistic regression analysis indicated that the combination of dRVVT with SCT was associated with total thrombotic events (odds ratio (OR) 5 11.5, 95% confidence interval (CI) 5 1.25-106.3, P 5 0.031) as well as with venous thrombosis (OR 5 4.09, 95% CI 5 1.16-14.43, P 5 0.028). According to our results, SCT is the most sensitive assay for identifying LA in patients who meet the clinical criteria for APS. Moreover, the highest sensitivity was reached with a combination of SCT and dRVVT. The method's association with total thrombotic events and venous thrombosis was in fact significant.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Use of a new silica clotting time for diagnosing lupus anticoagulant in patients who meet the clinical criteria for antiphospholipid syndrome

Grypiotis

Ruffatti

Pengo

et al. 2006

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…They enhance the thrombotic activity of aCL antibodies and the lupus anticoagulant (12) and have also been suggested to induce procoagulant proteins (13).…”

Section: Discussionmentioning

confidence: 99%

Dyslipidemia and its relationship with antiphospholipid antibodies in APS patients in North Kerala

et al. 2017

View full text Add to dashboard Cite

“…However, after the description by Krilis et al of the possible interaction between 2GPI and thrombin, the results which support the presence of distinct antibodies against thrombin must be critically re-evaluated [ 94 ]. As mentioned above, the effects of LA are caused by either anti-2GPI/ 2GPI complexes, by competitively inhibiting the formation of prothrombinase complex in vitro, or by anti-prothrombin (PT) /prothrombin complexes [ 15 ]. It has been supported by several studies that although anti-PT antibodies are involved in the activity of LA, these antibodies by themselves are not associated with thrombosis.…”

Section: Disruption Of Coagulation-fibrinolysis Balance 521 Enhancementioning

confidence: 99%

Pathogenic Mechanisms of Thrombosis in Antiphospholipid Syndrome (APS)

Sikara¹,

Grika²,

Vlachoyiannopoulos³

2011

Thrombophilia

View full text Add to dashboard Cite

β2-glycoprotein I–dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome

Cited by 208 publications

References 18 publications

Use of a new silica clotting time for diagnosing lupus anticoagulant in patients who meet the clinical criteria for antiphospholipid syndrome

Use of a new silica clotting time for diagnosing lupus anticoagulant in patients who meet the clinical criteria for antiphospholipid syndrome

Dyslipidemia and its relationship with antiphospholipid antibodies in APS patients in North Kerala

Pathogenic Mechanisms of Thrombosis in Antiphospholipid Syndrome (APS)

Contact Info

Product

Resources

About